

1 **Role of  $\beta$ -lactamases and efflux pumps in multidrug resistance in *Pseudomonas***  
2 ***aeruginosa* isolated from patients in the Intensive Care Unit in the northeast of**  
3 **Brazil**

4 Marília S. Maia <sup>1</sup> <sup>2</sup>#, Lavouisier F.B. Nogueira <sup>1</sup> <sup>2</sup>#, Marco A.F Clementino <sup>1</sup> <sup>2</sup>#, Jose  
5 Q.S. Filho <sup>1</sup> <sup>3</sup>, Ila F.N. Lima <sup>4</sup>, José K. Sousa <sup>1</sup>, Deiziane V.S. Costa <sup>1</sup>, Jorge L.N.  
6 Rodrigues <sup>4</sup>, Luciana V.C. Fragoso <sup>4</sup>, Alexandre Havt <sup>1</sup> <sup>2</sup>, and Aldo A.M. Lima <sup>1</sup> <sup>2</sup> <sup>3</sup> \*

7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

<sup>1</sup> Institute of Biomedicine, School of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

<sup>2</sup> Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

<sup>3</sup> Postgraduate Medical Sciences Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

<sup>4</sup> Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

\* Correspondence: [alima@ufc.br](mailto:alima@ufc.br)

# autores contribuíram igualmente para este trabalho

e-Mails: [mmaia800@gmail.com](mailto:mm Maia800@gmail.com), [lavouisier@gmail.com](mailto:lavouisier@gmail.com), [mclementino@ufc.br](mailto:mclementino@ufc.br),  
[jquirinof@gmail.com](mailto:jquirinof@gmail.com), [ila.lima@ebserh.gov.br](mailto:ila.lima@ebserh.gov.br), [jorge1207@gmail.com](mailto:jorge1207@gmail.com),  
[luciana.vladia@gmail.com](mailto:luciana.vladia@gmail.com), [ahavt@ufc.br](mailto:ahavt@ufc.br), [alima@ufc.br](mailto:alima@ufc.br)

22 **Abstract**

23 *Pseudomonas aeruginosa* is an opportunistic pathogen of great clinical relevance in  
24 intensive care units (ICU), mainly due to its high resistance to various antimicrobials,  
25 which sometimes makes effective treatment impossible, leading to high morbidity and  
26 mortality in patients in critical situations. In this study, we aimed to detect variants of  
27 genes encoding  $\beta$ -lactamases and efflux pumps in *P. aeruginosa* isolates resistant to  $\beta$ -  
28 lactams, fluoroquinolones and aminoglycosides. All genes belonging to the subfamilies  
29 were included in the study: *bla*<sub>SHV</sub>, *bla*<sub>TEM</sub>, *bla*<sub>NDM</sub>, *bla*<sub>KPC</sub>, *bla*<sub>GES</sub>, *bla*<sub>CTX-M</sub>. In addition,  
30 we investigate the most relevant variants of the *bla*<sub>OXA</sub> subfamily and genes belonging  
31 to the efflux pumps of the Mex family. We tested 54 isolates of *P. aeruginosa*, finding a  
32 high prevalence of phenotypic resistance to the antimicrobials piperacillin with  
33 tazobactam, ceftazidime, cefepime, imipenem and meropenem, with a high positivity in  
34 the presence of resistance genes related to carbapenems and spectrum  $\beta$ -lactamases  
35 extended, mainly for the *bla*<sub>KPC</sub> genes with 81.49%, followed by *bla*<sub>CTXM-2</sub> with 72.22%  
36 and *bla*<sub>CTXM-1</sub> with 66.66%. In relation to the presence of Mex family efflux pumps  
37 there was a rate of 100% of positivity. These results suggest that the *P. aeruginosa*  
38 strains isolated have an arsenal of genes encoding  $\beta$ -lactamases capable of inducing  
39 phenotypic patterns of resistance to several antimicrobials commonly used for these  
40 infections, making treatment difficult for the patients in this clinical ward.

41

42 **Key words:** *P. aeruginosa*; Antimicrobial Resistance;  $\beta$ -lactamases genes; efflux pumps  
43 genes; Intensive Care Unit.

44

45

## 46 **Introduction**

47 Antimicrobial-resistant Gram-negative bacteria (GNB) are of particular concern  
48 worldwide due to their high morbidity and mortality, particularly in intensive care units  
49 (ICUs) [1]. The emergence and spread of microbial resistance is a global problem that  
50 has profound consequences for public health and the economy [2].

51 Due to the selective pressure exerted by the frequent use of antimicrobials and  
52 the long stay of patients with compromised immune systems, infections related to  
53 multidrug-resistant (MDR) microorganisms are prevalent in ICU facilities [3,4].  
54 Healthcare-associated infections (HAIs) caused by MDR are considered a threat to  
55 public health, as they limit or even make available therapeutic options unfeasible, which  
56 increases the severity and, consequently, the morbidity and mortality rates of those  
57 affected, increasing patient length of stay and hospital costs [1].

58 In this scenario, *Pseudomonas aeruginosa*, an important opportunistic Gram-  
59 negative pathogen that causes a variety of infectious diseases, has acquired resistance to  
60 several antimicrobials in recent times [5,6]. According to the latest antimicrobial  
61 resistance surveillance report from the European Center for Disease Prevention and  
62 Control (ECDC), who evaluated *P. aeruginosa* isolates from 2013 to 2016, the average  
63 of *P. aeruginosa* isolates with combined resistance (resistance to three or more  
64 antimicrobial groups, including carbapenems) was 12.9% [7]. Furthermore, a study  
65 carried out in Singapore observed a percentage of 11.5% of health-related infections  
66 caused by *P. aeruginosa*, in which 23% of these isolates were resistant to carbapenems  
67 [8]. *P. aeruginosa* is included in the “critical” category of the World Health  
68 Organization (WHO) priority list of bacterial pathogens for which research and  
69 development of new antimicrobials are urgently needed [1].

70 The main mechanisms involved in antimicrobial resistance in *P. aeruginosa*  
71 strains are enzymatic mechanisms, where  $\beta$ -lactamases stand out, and efflux pumps.  
72 [5,9]. *P. aeruginosa* isolates contain a variety of  $\beta$ -lactamases, such as the  
73 carbapenemases KPC, GES, IMP, VIM, NDM and SPM, and are distributed throughout  
74 the world [10,11,12].

75 Efflux pumps are related to resistance to several antimicrobials, particularly  
76 those belonging to the AcrAB-TolC and Mex pump families belonging to the  
77 nodulation-division resistance superfamily (RND). Efflux pumps not only mediate  
78 intrinsic and acquired microbial resistance, but are also involved in other functions,  
79 including bacterial stress response and pathogenicity [13,14,15].

80 Based on this, we sought to detect variants of genes encoding  $\beta$ -lactamases and  
81 efflux pumps, belonging to the RND superfamily, in *P. aeruginosa* isolates resistant to  
82  $\beta$ -lactams, fluoroquinolones and aminoglycosides isolated from patients admitted to an  
83 intensive care ward a tertiary care health unit in the city of Fortaleza-CE, with the  
84 purpose of tracing the resistance profile of the strains isolated in the health unit in  
85 question.

## 86 **Material and methods**

### 87 **Obtaining bacterial isolates and identification**

88 For the following study, 259 samples were collected from patients admitted to  
89 the clinical ICU of a tertiary care health unit in the city of Fortaleza-CE, who presented  
90 an infectious condition (defined by the attending ward physicians) involving different  
91 anatomical sites. Those microorganisms that were identified as Gram-negative bacteria,  
92 resistant to one or more groups of antimicrobials were included:  $\beta$ -lactams,  
93 fluoroquinolones, aminoglycosides, macrolides, and glycopeptides. These samples were  
94 made available for the study through approval from the research ethics committee of the  
95 health unit in question (n° 3.276.113).

96 With the aim of diagnosing potential etiological agents, blood culture samples  
97 and other noble liquids were inoculated in specific bottles and incubated in the  
98 equipment BacT/Alert® 3D (BioMérieux, Marcy l'Etoile, France). The other biological  
99 materials were sown in specific culture media using a qualitative or quantitative sowing  
100 technique, in order to obtain isolated colonies. Plates were incubated at  $37\pm 2^\circ\text{C}$  for 18-  
101 24 hours.

102 The bacterial isolates were identified and tested for their susceptibility to  
103 antimicrobials using the automated method VITEK® 2 Compact (BioMérieux, Marcy  
104 l'Etoile, France), according to the manufacturer's recommendations. Minimum  
105 inhibitory concentrations were interpreted according to the Clinical and Laboratory  
106 Standards Institute [16] and with the Brazilian committee on antimicrobial susceptibility  
107 testing [17,18]. For quality control of sensitivity tests, strains from the American Type

108 Culture Collection (ATCC) were used. Specimens that had a resistance profile that fit  
 109 the research objectives were included in the study.

### 110 Selection of analyzed strains

111 A total of 258 isolates were analyzed, among which those identified as *P.*  
 112 *aeruginosa* were included in this study. Strains of *P. aeruginosa* resistant to one or  
 113 more groups of  $\beta$ -lactam antimicrobials, fluoroquinolones and aminoglycosides were  
 114 then used to investigate their genetic resistance profile. MDR was defined as multidrug  
 115 resistant to  $\geq 1$  agent in  $\geq 3$  classes of antimicrobials and extending drug resistance  
 116 (XDR) as drug susceptibility to  $\leq 2$  classes of antimicrobials agents.

### 117 Extraction of bacterial DNA

118 The isolates maintained in trypticase soy broth were incubated overnight in a  
 119 bacteriological oven at 37°C, at 200 rpm, for subsequent extraction of bacterial DNA.  
 120 To extract genetic material, the Wizard Genomic DNA Purification extraction and  
 121 purification kit was used (Promega, Madison, USA), according to the manufacturer's  
 122 recommendations.

123 After extraction, all samples were quantified by spectrophotometry using the  
 124 NanoDrop™ 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and  
 125 stored in a -80°C freezer until used in the experiments.

### 126 Detection of resistance-related genes by molecular biology

127 The selected strains of *P. aeruginosa* were analyzed by real-time PCR (qPCR)  
 128 using QuantStudio 3® (Applied Biosystems, Massachusetts, USA), using specific  
 129 primers, for the detection of 13 genes encoding efflux pumps (**Table 1**) and 14 genes  
 130 encoding  $\beta$ -lactamases described by Nogueira and collaborators [19]. Reactions were  
 131 standardized using positive controls and negative controls (milliQ water) to determine  
 132 the most efficient qPCR conditions.

133 **Table 1** Description of genes related to encoding efflux pumps.

Efflux pumps	Gene	Function	Primers	Primer sequence (5'-3')	Product size (bp)	At (°C)
MexAB-OprM	mexA	membrane fusion protein	MexA F	GACAAGTGGCTGGTTACCGA	96	63
			MexA R	CACGGTCTTCACCTCGACAC		
	mexB	Inner membrane	MexB F	GTCGATCCGTTCTCGGTGA	158	65

		transporter	MexB R	ACTCCACGATGAGAATGGCG		
MexCD-OprJ	mexC	membrane fusion protein	MexC F	CGTGCAATAGGAAGGATCGG	104	60
			MexC R	TCCACCGGCAACACCATTT		
	mexD	Inner membrane transporter	MexD F	TACACCCTGATCCCGTCCAT	170	64
			MexD R	ATGATCCGCTCGACGTTCTC		
MexEF-OprN	mexE	membrane fusion protein	MexE F	CTGAGCTTCACCCGGATCAC	140	64
			MexE R	GCGTCGAAGTAGGCGTAGAC		
	mexF	Inner membrane transporter	MexF F	TCATCAAGGTCAGCGACACC	169	64
			MexF R	CACTCGTAGGTCATGCCGTT		
MexGHI-OpmD	mexG	membrane protein	MexG F	TGCAGCGCTTCATCGATAACT	120	64
			MexG R	GGCTGGCCTGATAGTCGAAC		
	mexH	membrane fusion protein	MexH F	TCATCAAGGTCAGCGACACC	124	65
			MexH R	CACTCGTAGGTCATGCCGTT		
MexVW-OprM	mexV	membrane fusion protein	MexV F	TACTGTTCCCTTCCGGCGAC	170	61
			MexV R	TTCGCTTTTCGAGATGGCCT		
	mexW	membrane protein	MexW F	CCTCGGTCTACATCGGCATC	181	65
			MexW R	CCGAGGGTCTTCACTTTC		
MexXY-OprM	mexX	membrane protein	MexX F	TGCTGTTCCAGATCGACCCT	127	60
			MexX R	TCCTTGATCAGGTCGGCGTA		
	mexY	membrane fusion protein	MexY F	GTCAACCAAATGACCGCCAC	134	65
			MexY R	ATGTTGTAGCTCACGCCCTC		

134 At= Annealing temperature

135 Bp= Base pairs; Primer F = Forward; Primer R = Reverse

## 136 Data Analysis

137 Fisher's test was used to compare the proportion of occurrence of a variable  
138 between groups. The confidence interval was 95% and the test was considered  
139 statistically significant when  $P < 0.05$ , using the IBM Statistical Package for the Social  
140 Sciences Version 21 program (SPSS Statistics Software, Nova York, EUA).

## 141 Results

### 142 Prevalence of *P. aeruginosa* in the study

143 During the period of this study, 258 Gram-negative bacteria were isolated, of  
144 which 20.9% (54/258) were identified as *P. aeruginosa*, which were isolated from  
145 different anatomical sites of hospitalized patients. The tracheal aspirate was the sample  
146 that obtained the highest number of *P. aeruginosa* isolates with 74.1% (40/54), followed  
147 by blood samples with 11.11% (6/54), bronchoalveolar lavage 7.40 % (4/54), of  
148 abdomen 1.85% (1/54), of tissue fragment 1.85% (1/54), of sacral eschar 1.85% (1/54)  
149 and of tendon 1, 85% (1/54).

### 150 Antimicrobial resistance phenotype tested in *P. aeruginosa* isolates

151 Fifteen antimicrobials from different classes were tested, in which *P.*  
152 *aeruginosa* isolates obtained a resistance rate of 100% to cefoxitin (32/32),

153 ceftriaxone (25/25), cefuroxime axetil (32/32) and tigecycline (32/32), thus  
154 confirming the intrinsic resistance of the pathogen to these antimicrobials. The  
155 combination of piperacillin with tazobactam obtained a rate of 74.4% (32/43),  
156 followed by ceftazidime and cefepime both with the same percentage of 63.4%  
157 (33/52), imipenem with 61.2% (30/ 49), meropenem with 56.2% (27/48),  
158 ciprofloxacin 54.9% (28/51), gentamicin 41.5% (22/53) and, finally, amikacin with  
159 28.3% (15/ 53), as shown in **Figure 1**. All tested isolates did not demonstrate a  
160 phenotype of resistance to colistin, ceftazidime / avibactam and  
161 ceftolozone/tazobactam.

162

163 **Figure 1.** Prevalence of *P. aeruginosa* isolates resistant to  $\beta$ -lactam antimicrobials  
164 (A) and aminoglycosides, quinolones and glycylicycline (B) evaluated, demonstrating  
165 a phenotypic profile of resistance to multiple antimicrobials in more than 50% of the  
166 isolates, with the exception of colistin, ceftazidime/ avibactam, ceftolozone/  
167 tazobactam, gentamicin and amikacin.

168 The tested isolates of *P. aeruginosa* obtained a percentage of 61.11% (33/54)  
169 for MDR microorganisms, followed by a percentage of 55.5% (30/54) for XDR  
170 microorganisms and a percentage of 46.2% (25/54) for carbapenem-resistant  
171 microorganisms.

## 172 **Detection of resistance genes in *P. aeruginosa* isolates by qPCR**

173 For the detection of genes encoding  $\beta$ -lactamases, the highest percentage  
174 found was the *bla*<sub>KPC</sub> gene with 81.49% (44/54), followed by *bla*<sub>CTXM-2</sub> with 72.22%  
175 (39/54), *bla*<sub>CTXM-1</sub> with 66.66% (36/54), *bla*<sub>CTXM-5</sub> with 59.25% (32/54), *bla*<sub>SHV</sub> with  
176 40.74% (22/54), *bla*<sub>TEM</sub> and *bla*<sub>OXA-23-like</sub> with 38.89% (21/54), *bla*<sub>NDM</sub> with 29.6%  
177 (16/54), *bla*<sub>GES</sub> and *bla*<sub>OXA-51-like</sub> with 24% (13/54), *bla*<sub>OXA-24/40-like</sub> with 20.4% (11/54),  
178 *bla*<sub>CTXM-3</sub> with 11.11% (6/54), *bla*<sub>CTXM-4</sub> with 9.26% (5/54) and there was no detection  
179 of the *bla*<sub>OXA-48-like</sub> gene in the isolates, as shown in **Figure 2**, grouped according to  
180 the Ambler classification.

181

182 **Figure 2.** Prevalence of  $\beta$ -lactam resistance genes among *P. aeruginosa* isolates,  
183 grouped according to the Ambler classification, (A) in which there is a high detection

184 rate for class A ESBL (*bla*<sub>CTX-M</sub> do clade 2, 1 and 5 respectively; *bla*<sub>SHV</sub>; *bla*<sub>TEM</sub>), (B)  
 185 marked presence of the *bla*<sub>KPC</sub> carbapenemase, (C) in addition to the identification of  
 186 *bla*<sub>OXA-23-like</sub>, *bla*<sub>OXA-51-like</sub> and *bla*<sub>OXA-24/40-like</sub> commonly associated with *Acinetobacter*  
 187 *baumannii* strains.

## 188 Association of the presence of resistance genes with the resistance phenotype

189 The association between the prevalence of the 14 genes encoding  $\beta$ -lactamases  
 190 and the  $\beta$ -lactam resistance phenotype identified in *P. aeruginosa* isolates was  
 191 evaluated. The distribution of the percentage of genes detected in the isolates tested  
 192 for the antimicrobials cefepime and ceftazidime showed a higher positivity rate for  
 193 the genes *bla*<sub>KPC</sub>, *bla*<sub>CTXM-2</sub>, *bla*<sub>CTXM-1</sub>, *bla*<sub>CTXM-5</sub>, *bla*<sub>SHV</sub> with 82.7% (43/52), 75%  
 194 (39/52), 69.2% (36/52), 61.5% (32/52) and 42.3% (22/52), respectively. The presence  
 195 of the *bla*<sub>TEM</sub> and *bla*<sub>OXA-23-like</sub> genes were associated with phenotypic resistance to the  
 196 antimicrobials cefepime and ceftazidime (P= 0.017; OR 5.66; 95% CI 1.38-23.21)  
 197 and (P=0.041; OR 3.98; 95% CI 1.08 – 14.58), respectively, as shown in **Table 2**.

198 **Table 2** Percentage of positivity of genes encoding  $\beta$ -lactamases in *P. aeruginosa*  
 199 isolates in the groups resistant and susceptible to the antimicrobials cefepime and  
 200 ceftazidime.

Coding genes $\beta$ -lactamases	Total N=52(%)	Resistant N=33(%)	Susceptible N=19(%)	P valor	OR	95% CI
<i>bla</i> <sub>KPC</sub>	43 (82.7)	27 (81.8)	16 (84.2)	1.0000	0.84	0.18 – 3.85
<i>bla</i> <sub>CTXM-2</sub>	39 (75)	25 (75.8)	14 (73.7)	1.0000	1.11	0.30 – 4.07
<i>bla</i> <sub>CTXM-1</sub>	36 (69.2)	24 (72.7)	12 (63.2)	0.5405	1.55	0.46 – 5.20
<i>bla</i> <sub>CTXM-5</sub>	32 (61.5)	19 (57.6)	13 (68.4)	0.5579	0.62	0.19 – 2.05
<i>bla</i> <sub>SHV</sub>	22 (42.3)	13 (39.4)	9 (47.37)	0.3969	0.58	0.18 – 1.82
<i>bla</i> <sub>OXA-23-like</sub>	21 (40.4)	17 (51.5)	4 (21)	<b>0.041*</b>	3.98	1.08 – 14.58
<i>bla</i> <sub>TEM</sub>	20 (38.5)	17 (51.5)	3 (15.8)	<b>0.017*</b>	5.66	1.38-23.21
<i>bla</i> <sub>NDM</sub>	16 (30.7)	10 (30.3)	6 (31.6)	1.0000	0.94	0.27 – 3.19
<i>bla</i> <sub>GES</sub>	13 (25)	8 (24.2)	5 (26.3)	1.0000	0.89	0.24 – 3.27
<i>bla</i> <sub>OXA-51-like</sub>	13 (25)	11 (33.3)	2 (10.5)	0.0987	4.25	0.82 – 21.79
<i>bla</i> <sub>OXA-24/40-like</sub>	10 (19.2)	8 (24.2)	2 (10.5)	0.2925	2.72	0.51 – 14.42
<i>bla</i> <sub>CTXM-3</sub>	6 (11.5)	3 (9)	3 (15.8)	0.6563	0.53	0.09 – 2.95

<i>bla</i> <sub>CTXM-4</sub>	5 (9.3)	4 (12.1)	1 (5.3)	0.6410	2.48	0.25 – 24.02
<i>bla</i> <sub>OXA-48-like</sub>	0	0	0	0	0	0

201 OR= *Odds ratio*; CI= Confidence interval.

202 The most frequently identified genes in the isolates tested for the antimicrobial  
 203 piperacillin in combination with the  $\beta$ -lactamase inhibitor tazobactam were *bla*<sub>KPC</sub>,  
 204 *bla*<sub>CTXM-2</sub>, *bla*<sub>CTXM-1</sub>, *bla*<sub>CTXM-5</sub>, *bla*<sub>SHV</sub> and *bla*<sub>OXA-23-like</sub> with percentages of 81.4% (  
 205 35/43), 74.4% (32/43), 67.4% (29/43), 65.1% (28/43), 41.8% (18/43) and 41.8% (  
 206 18/43), respectively. There was no statistical significance between the genes studied  
 207 and the phenotype.

208 The percentage of positivity of the genes encoding  $\beta$ -lactamases detected in  
 209 the isolates tested for the antimicrobial imipenem indicated a higher positivity rate for  
 210 the genes *bla*<sub>KPC</sub>, *bla*<sub>CTXM-2</sub>, *bla*<sub>CTXM-1</sub>, *bla*<sub>CTXM-5</sub> and *bla*<sub>SHV</sub> with percentages of  
 211 79.6% (39/49), 71.4% (35/49), 67.3% (33/49), 57.1% (28/49) and 38.7% (19/49),  
 212 respectively. The presence of the *bla*<sub>TEM</sub> gene achieved statistical significance with  
 213 phenotypic resistance to the antimicrobial imipenem (P=0.018; OR 5.33; 95% CI  
 214 1.28-22.20), as shown in **Table 3**.

215 **Table 3** Percentage of positivity of genes encoding  $\beta$ -lactamases in *P. aeruginosa*  
 216 isolates in the resistant and susceptible groups to the antimicrobial imipenem.

Coding genes $\beta$ -lactamases	Total N=49(%)	Resistant N=30(%)	Susceptible N=19(%)	P valor	OR	95% CI
<i>bla</i> <sub>KPC</sub>	39 (79.6)	24 (80)	15 (78.9)	1.0000	1.06	0.25 – 4.41
<i>bla</i> <sub>CTXM-2</sub>	35 (71.4)	20 (66.6)	15 (78.9)	0.5185	0.53	0.13 – 2.03
<i>bla</i> <sub>CTXM-1</sub>	33 (67.3)	19 (63.3)	14 (73.7)	0.5412	0.61	0.17 – 2.18
<i>bla</i> <sub>CTXM-5</sub>	28 (57.1)	15 (50)	13 (68.4)	0.2467	0.46	0.13 – 1.53
<i>bla</i> <sub>SHV</sub>	19 (38.7)	10 (33.3)	9 (47.3)	0.3774	0.55	0.17 – 1.80
<i>bla</i> <sub>OXA-23-like</sub>	18 (36.7)	13 (43.3)	5 (26.3)	0.3621	2.14	0.61 – 7.48
<i>bla</i> <sub>TEM</sub>	18 (36.7)	15 (50)	3 (15.7)	<b>0.018*</b>	5.33	1.28 – 22.20
<i>bla</i> <sub>NDM</sub>	15 (30.6)	7 (23.3)	8 (42.1)	1.0000	0.87	0.27 – 2.81
<i>bla</i> <sub>OXA-51-like</sub>	12 (24.5)	10 (33.3)	2 (10.5)	0.0948	4.25	0.81 – 22.14
<i>bla</i> <sub>GES</sub>	12 (24.5)	6 (20)	6 (31.6)	0.4975	0.54	0.14 – 2.02
<i>bla</i> <sub>OXA-24/40-like</sub>	8 (16.3)	6 (20)	2 (10.5)	0.4583	2.12	0.38 – 11.83

<i>bla</i> <sub>CTXM-3</sub>	5 (10.2)	3 (10)	2 (10.5)	1.0000	0.94	0.14 – 6.25
<i>bla</i> <sub>CTXM-4</sub>	3 (6.1)	3 (10)	0	0.2730	4.96	0.24 – 101.7
<i>bla</i> <sub>OXA-48-like</sub>	0	0	0	0	0	0

217 OR= Odds ratio; CI= Confidence interval.

218 The distribution of the percentage of positivity of the genes encoding  $\beta$ -  
 219 lactamases detected in the isolates tested for the antimicrobial meropenem showed a  
 220 higher rate for the genes *bla*<sub>KPC</sub>, *bla*<sub>CTXM-2</sub>, *bla*<sub>CTXM-1</sub>, *bla*<sub>CTXM-5</sub> and *bla*<sub>SHV</sub> with  
 221 percentages of 79.6% (39/49), 71.4% (35/49), 67.3% (33/49), 57.1% (28/49) and 38.7%  
 222 (19/49), respectively. The presence of *bla*<sub>TEM</sub> and *bla*<sub>OXA-51-like</sub> genes achieved statistical  
 223 significance with phenotypic resistance to the antimicrobial meropenem (P= 0.034; OR  
 224 4.57; 95% CI 1.21-17.23) and (P=0.043; OR 5 .58; 95% CI 1.06 – 29.20), respectively,  
 225 as shown in **Table 4**.

226 **Table 4** Percentage of positivity of genes encoding  $\beta$ -lactamases in *P. aeruginosa*  
 227 isolates in the resistant and susceptible groups to the antimicrobial meropenem.

Coding genes $\beta$ -lactamases	Total N=48(%)	Resistant N=27(%)	Susceptible N=21(%)	P valor	OR	95% CI
<i>bla</i> <sub>KPC</sub>	38 (79.1)	21 (77.7)	17 (80.9)	1.0000	0.82	0.19 – 3.40
<i>bla</i> <sub>CTXM-2</sub>	35 (72.9)	18 (66.6)	17 (80.9)	0.3377	0.47	0.12 – 1.81
<i>bla</i> <sub>CTXM-1</sub>	35 (72.9)	19 (70.3)	16 (76.2)	0.7502	0.74	0.20 – 2.72
<i>bla</i> <sub>CTXM-5</sub>	28 (58.3)	13 (48.1)	15 (71.4)	0.1437	0.37	0.11 – 1.24
<i>bla</i> <sub>SHV</sub>	21 (43.7)	10 (37)	11 (52.4)	0.3820	0.53	0.16 – 1.70
<i>bla</i> <sub>OXA-23-like</sub>	19 (39.5)	13 (48.1)	6 (28.6)	0.2369	2.32	0.69 – 7.79
<i>bla</i> <sub>TEM</sub>	18 (37.5)	14 (51.8)	4 (19)	<b>0.034*</b>	4.57	1.21 – 17.23
<i>bla</i> <sub>NDM</sub>	16 (33.3)	7 (25.9)	9 (42.8)	0.2373	0.46	0.13 – 1.58
<i>bla</i> <sub>OXA-51-like</sub>	12 (25)	10 (37)	2 (9.5)	<b>0.043*</b>	5.58	1.06 – 29.20
<i>bla</i> <sub>GES</sub>	13 (27)	6 (22.2)	7 (33.3)	0.5161	0.57	0.15 – 2.06
<i>bla</i> <sub>OXA-24/40-like</sub>	8 (16.6)	6 (22.2)	2 (9.5)	0.4371	2.71	0.48 – 15.11
<i>bla</i> <sub>CTXM-3</sub>	6 (12.5)	3 (11.1)	3 (14.3)	1.0000	0.75	0.13 – 4.16
<i>bla</i> <sub>CTXM-4</sub>	2 (4.2)	2 (7.4)	0	0.4973	4.21	0.19 – 92.73
<i>bla</i> <sub>OXA-48-like</sub>	0	0	0	0	0	0

228 OR= Odds ratio; CI= Confidence interval.

229 The genes that encode the efflux pumps of the MEX family were evaluated by  
230 operon, in which the distribution of the percentage of positivity found in the tested  
231 isolates was 100% for the genes MEX-AB, MEX-EF, MEX-GH, MEX-VW, MEX-XY  
232 and followed by a percentage of 96.3% for the MEX-CD gene. No statistical tests were  
233 performed regarding efflux pumps due to the high positivity of the genes.

## 234 **Discussion**

235 *P. aeruginosa* is an opportunistic pathogen with considerable clinical importance  
236 in intensive care units, mainly due to its high resistance to several antimicrobials,  
237 making effective treatment impossible, leading to high morbidity and mortality in these  
238 patients in critical situations [20].

239 This study found a prevalence of 20.9% of colonization by this microorganism,  
240 among Gram-negative isolates resistant to at least one antimicrobial, which represents a  
241 similar percentage with other studies, as demonstrated in a report issued by ANVISA  
242 [21], where *P. aeruginosa* was the third most isolated microorganism among Gram-  
243 negative bacteria reported in bloodstream infections, with a percentage of 16.2%. In the  
244 United States, Sader and collaborators, analyzing samples of Gram-negative bacteria  
245 isolated from ICU and non-ICU patients, collected in 70 hospital centers, from 2018 to  
246 2020, found a prevalence of 23.5% of *P. aeruginosa* isolated in patients admitted to  
247 ICU [22]. Dunphy and collaborators carried out a study in outpatient and hospital  
248 environments in regions of Virginia, United States, over a period of one year (2019-  
249 2020), collecting several samples, in which they identified a prevalence of 60% of *P.*  
250 *aeruginosa* isolates from different anatomical sites, analyzing 971 isolates collected  
251 from 590 patients [23], in which these studies demonstrate a variability in the detection  
252 rate of this pathogen.

253 In this study, the largest number of *P. aeruginosa* isolates was obtained through  
254 bronchial lavage secretions with a percentage of 74.1%, similar results were reported in  
255 other studies in which *P. aeruginosa* was the most isolated pathogen in lung secretions  
256 (bronchial lavage and tracheal aspirate) [23,24]. Respiratory infections caused by this  
257 pathogen are quite common, especially in hospital environments, and may be related to  
258 the handling of invasive procedures on patients, such as tracheal intubation, aspirations  
259 and the need for mechanical pulmonary ventilation [11,20].

260 In order to identify the phenotypic profile of antimicrobial resistance of *P.*  
261 *aeruginosa* strains isolated in the hospital environment, antimicrobials from different

262 classes were tested, in which the highest resistance rate of *P. aeruginosa* isolates was  
263 100% for cephalosporins of second and third generation cefoxitin, ceftriaxone and  
264 cefuroxime axetil. Several studies corroborate this result demonstrating that the only  
265 third generation cephalosporin with action on strains of *P. aeruginosa* is ceftazidime  
266 [25,26].

267 In agreement with the findings of this study, research carried out in the United  
268 States by Sader and collaborators [22] on *P. aeruginosa* strains collected over a two-  
269 year period and a study carried out in Rio de Janeiro over a 20-year period [27], found  
270 similar results for the antimicrobials piperacillin with tazobactam, ceftazidime,  
271 cefepime and meropenem in strains of *P. aeruginosa*. These studies indicated a growing  
272 increase in the rate of resistance to antimicrobials over the years.

273 Regarding third-generation cephalosporins in combination with  $\beta$ -lactamases  
274 inhibitors (ceftazidime with avibactam and ceftolozone with tazobactam), in our study  
275 there was no detection of the resistance phenotype. This result is in line with what was  
276 expected since ceftolozone with tazobactam is an antipseudomonal antimicrobial that  
277 acts on multidrug-resistant strains of *P. aeruginosa* [28,29]. The antimicrobial  
278 ceftazidime with avibactam acts on multidrug-resistant *P. aeruginosa* strains that are  
279 ESBL, AmpC and KPC positive, as this inhibitor removes the serine residue that is the  
280 active portion of the enzyme, however, these antimicrobials do not act on metallo  $\beta$ -  
281 lactamases positive strains [30], indicating the action of  $\beta$ -lactamases inhibitors in light  
282 of the high positivity of the presence of genes encoding KPC in our study.

283 The susceptibility rates obtained in our study are in agreement with studies that  
284 have reported good activity of ceftazidime associated with avibactam and ceftolozone  
285 associated with tazobactam. López-Calleja and collaborators [31] carried out a study in  
286 a university hospital located in Spain, in which they analyzed the susceptibility profile  
287 of 12 MDR strains of *P. aeruginosa* and 117 XDR strains of *P. aeruginosa* against  
288 ceftolozone associated with tazobactam, and detected a susceptibility rate of 92.2% in  
289 these isolates. In the same context, research carried out by the Global Antimicrobial  
290 Testing Leadership and Surveillance Program, collected 2.521 clinical isolates of *P.*  
291 *aeruginosa* from 41 medical centers in 10 countries in Latin America, from 2017 to  
292 2019, in which they found a rate of 86.9% of isolates susceptible to ceftazidime  
293 associated with avibactam [32]. Therefore, these studies corroborate our results,  
294 showing that third-generation cephalosporins in combination with  $\beta$ -lactamases  
295 inhibitors are a good therapeutic option.

296 In order to identify the presence and prevalence of genes encoding  $\beta$ -lactamases  
297 in the university hospital, we analyzed 14 genes, where the most prevalent gene was  
298 *bla*<sub>KPC</sub> with 81.49% positivity in the isolates. In a study carried out by Hu and  
299 collaborators [33], researching strains of carbapenem-resistant *P. aeruginosa* isolated  
300 from the intestine, from 2014 to 2019, the presence of the *bla*<sub>KPC-2</sub> gene was identified in  
301 21.1% of the isolates. Likewise, a prospective and observational cohort study, carried  
302 out from 2018 to 2019, analyzed 972 patients admitted with confirmed infection by  
303 carbapenem-resistant *P. aeruginosa* in 44 hospitals, distributed across three continents,  
304 identifying the presence of the *bla*<sub>KPC-2</sub> gene in 49% of isolates, demonstrating the  
305 circulation of this gene that confers resistance to carbapenems in various parts of the  
306 world [34]. Carbapenems have the widest spectrum of action for the treatment of  
307 infections caused by multidrug-resistant bacteria, which is why the emergence and  
308 spread of carbapenemases has become a major public health problem. Our study  
309 detected a rate well above the studies cited, as we used a *bla*<sub>KPC</sub> primer that detects 19  
310 variants, expanding the detection of this  $\beta$ -lactamase, in contrast to just one variant that  
311 the studies above investigated.

312 To understand the association of the  $\beta$ -lactam resistance phenotype with genes  
313 related to  $\beta$ -lactamases, we correlated the phenotype and genotype and found a  
314 statistical association between resistance to ceftazidime and cefepime with the presence  
315 of the *bla*<sub>TEM</sub> and *bla*<sub>OXA-23-like</sub> genes. This can be explained by the fact that the *bla*<sub>TEM</sub>  
316 gene has several variants that are ESBLs, capable of hydrolyzing third and fourth  
317 generation cephalosporins [35]. In this case, our study used primers that have the ability  
318 to detect 167 variants of the *bla*<sub>TEM</sub> gene, of which many of these variants are ESBLs.  
319 Regarding the *bla*<sub>OXA-23-like</sub> gene, which encodes an enzyme capable of hydrolyzing all  
320 cephalosporins and carbapenems [36,37], was the first class D carbapenemase to be  
321 discovered in a strain of *Acinetobacter baumannii*, in 1985, coincidentally the same  
322 year that imipenem was approved for clinical use [38]. Genes belonging to the *bla*<sub>OXA-  
323 23-like</sub> group can be transmitted by plasmids between species, in which studies have  
324 detected the role of plasmids and transposons in the dissemination of the *bla*<sub>OXA-23</sub> gene,  
325 which has been found in *Acinetobacter* spp., *P. aeruginosa*, as well as species belonging  
326 to the *Enterobacteriaceae* [36,39,40,41].

327 The presence of the *bla*<sub>TEM</sub> gene was also associated with resistance to  
328 carbapenems, imipenem and meropenem; there is no previous information in the  
329 literature that corroborates this result in *P. aeruginosa*. However, a study carried out by

330 Han and colleagues [42], analyzing strains of *A. baumannii* resistant to carbapenems in  
331 a university hospital in China, found an association between the presence of the *bla*<sub>TEM</sub>  
332 and *bla*<sub>OXA-23-like</sub> genes with the carbapenem resistance phenotype. In research carried  
333 out in an Iranian hospital, from 2015 to 2017, resistant strains of *P.aeruginosa* were  
334 isolated from patients with nosocomial and non-nosocomial infections and the presence  
335 of the *bla*<sub>OXA-23-like</sub> gene was identified in 11.19% of the isolates [43], evidencing the  
336 circulation of the OXA group gene in species other than *Acinetobacter*.

337 Finally, the presence of the *bla*<sub>OXA-51-like</sub> gene was associated with resistance to  
338 meropenem. *bla*<sub>OXA-51-like</sub> encodes a carbapenemase belonging to Ambler class D, which  
339 are enzymes intrinsic to *A. baumannii* and are found naturally in the chromosome of this  
340 species [36], however, in 2009, Lee and colleagues reported the presence of the *bla*<sub>OXA-</sub>  
341 <sub>51</sub> gene in a non-*Acinetobacter* species, in which they identified this gene with an  
342 ISAbal insertion, which was plasmid-encoded and the surrounding sequences suggested  
343 that its origin was from *A. baumannii*. In this study, the enzyme encoded by *bla*<sub>OXA-51</sub>  
344 had the capacity to increase the minimum inhibitory concentration (MIC) of meropenem  
345 by up to 256 times, thus conferring resistance to it [44]. However, there is only one  
346 study in the literature that reports the presence of the *bla*<sub>OXA-51</sub> gene in *P. aeruginosa*  
347 strains, which were isolated from outpatients in Maranhão, Brazil [45]. These studies  
348 demonstrate the spread of the *bla*<sub>OXA-51</sub> gene beyond strains of *A. baumannii*, where this  
349 gene was considered a marker for these species.

350 Regarding the presence of Mex family efflux pumps in *P. aeruginosa* isolates,  
351 our study showed a positivity of 96.3% for the gene that encodes the MexCD pump and  
352 a positivity of 100% for the rest of the Mex pumps tested. There was no statistical  
353 association of efflux pumps in relation to the resistance phenotype due to the high  
354 positivity in the isolates, but studies have shown that efflux pumps in *P. aeruginosa* are  
355 among one of the main resistance mechanisms that lead to the emergence of MDR  
356 strains and XDR. This primary resistance mechanism is responsible for reducing the  
357 intracellular concentration of the drug to a subinhibitory concentration at which other  
358 resistance mechanisms for specific classes can evolve and be selected, increasing  
359 antimicrobial resistance [46,47].

360 The present study had some limitations, such as: susceptible strains of *P.*  
361 *aeruginosa* were not included in the study for a more detailed epidemiological analysis,  
362 no research was carried out into the existence of clones of *P. aeruginosa* circulating in  
363 the ICU, no sequencing was carried out positive controls for a more precise validation

364 of all variants that our method aims to detect and the isolates were not tested for all  
365 antimicrobials in a homogeneous way due to clinical implications and procedures  
366 adopted by the hospital analyzed in the study. However, our work innovated in the use  
367 of primers that could detect a greater number of genes encoding  $\beta$ -lactamases, thus  
368 expanding their diagnosis.

369 The *P. aeruginosa* strains isolated in this study showed a high rate of phenotypic  
370 resistance to several antimicrobials, in which these strains have a repertoire of genes  
371 encoding  $\beta$ -lactamases capable of inducing these phenotypic patterns of resistance to  
372 antimicrobials commonly used for these infections, making treatment difficult or even  
373 impossible for the patient.

#### 374 **Author Contributions:**

375 Bibliographic review and data collection, Marília S. Maia, Lavouisier F.B. Nogueira,  
376 Marco A.F Clementino and Aldo A.M. Lima; Methodology, Lavouisier F.B. Nogueira,  
377 Marília S. Maia, Marco A.F Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N.  
378 Rodrigues, Luciana V. C. Fragoso and Aldo A. M. Lima; Bioinformatics, Lavouisier  
379 F.B. Nogueira and Marco A.F Clementino; *In vitro* validation of primers and sample  
380 testing, Marília S. Maia, Lavouisier F.B. Nogueira,; Data analysis, Jose Q.S. Filho;  
381 Deiziane V.S. Costa, José K. Sousa, and Aldo A.M. Lima.

382 Written review and editing, Marília S. Maia, Lavouisier F.B. Nogueira, and Aldo A.M.  
383 Lima; Supervision, Alexandre Havt and Aldo A.M. Lima; Project administration, Aldo  
384 A.M. Lima; Resource acquisition, Aldo A.M. Lima.

385 **Funding:** This research was funded by CNPq (<http://www.cnpq.br>), grant numbers  
386 402607/2018-0 and 408549/2022-0 and FUNCAP (<https://www.funcap.ce.gov.br/>),  
387 grant number: OFÍCIO N° 102/2021 – DINOVA.

388 **Data Availability Statement:** The data and reports relating to this study will be  
389 available via direct request via email to the corresponding author.

390 **Conflicts of Interest:** The authors declare that there are no financial or personal  
391 conflicts of interest that may have influenced the work.

#### 392 **References**

393 1. WHO. Media Center. WHO publishes list of bacteria for which new antibiotics are  
394 urgently needed. World Health Organization: 27 Feb., 2017.

- 395 2. FLEECE, ME. et al. Molecular diagnosis of antimicrobial resistance in *Escherichia*  
396 *coli*. **Expert Rev Mol Diagn**, v.18, n. 3, p.207-217, 2018.
- 397 3. AMARAL, MVF et al. Prevalência de microorganismos multirresistentes em um  
398 hospital universitário - análise de uma série histórica. In: II Congresso Brasileiro de Medicina  
399 Hospitalar - II CBMH. **Blucher Medical Proceedings**, v 1, n 5, p.70, 2014.
- 400 4. CARVALHO, MR. et al. Incidência de bactérias multirresistentes em uma unidade de  
401 terapia intensiva. **Revista Interdisciplinar**, v.8, n.2, p. 75-85, 2015.
- 402 5. BOTELHO, J.; GROSSO, F.; PEIXE, L. Antibiotic resistance in *Pseudomonas*  
403 *aeruginosa* – Mechanisms, epidemiology and evolution, **Drug Resistance Updates**, v. 44,  
404 p.26–47, 2019.
- 405 6. JURADO-MARTÍN, I.; SAINZ-MEJÍAS, M.; MCCLEAN, S. *Pseudomonas*  
406 *aeruginosa*: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. **Int. J.**  
407 **Mol. Sci.** v.22, p.3128, 2021.
- 408 7. EUROPEAN CENTER FOR DISEASE PREVENTION AND CONTROL (ECDC),  
409 Surveillance of antimicrobial resistance in Europe, Annual report of the European Antimicrobial  
410 Resistance Surveillance Network (EARS-Net), 2016.
- 411 8. CAI, Y. et al. Prevalence of Healthcare- Associated Infections and Antimicrobial Use  
412 Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National  
413 Point Prevalence Survey. **Clin Infect Dis.** v.64, n. 2, p.S61–S67, 2017.
- 414 9. ROSSI, E. et al. *Pseudomonas aeruginosa* adaptation and evolution in patients with  
415 cystic fibrosis. **Nat. Rev. Microbiol.** v.19, p.331–342, 2021.
- 416 10. ESCANDÓN-VARGAS K. et al. The epidemiology of carbapenemases in Latin  
417 America and the Caribbean. **Expert Rev Anti Infect Ther.** 2017 Mar;15(3):277–297.
- 418 11. TENOVER, FC.; NICOLAU, DP.; Gill, CM. Carbapenemase-producing *Pseudomonas*  
419 *aeruginosa* -an emerging challenge. **Emerg Microbes Infect.** v.11, n.1, p.811-814, 2022.
- 420 12. WALTERS MS. et al. Carbapenem- resistant *Pseudomonas aeruginosa* at US Emerging  
421 infections program sites, 2015. **Emerging Infect Dis.** 2019 Jul;25(7):1281–1288.
- 422 13. LI, XZ.; PLÉSIAT, P.; NIKAIDO, H. The challenge of efflux-mediated antibiotic  
423 resistance in Gram-negative bacteria. **Clin Microbiol Rev.** v. 28, n. 2, p.337-418, 2015.
- 424 14. LV, L. et al. Emergence of a Plasmid-Encoded Resistance-NodulationDivision Efflux  
425 Pump Conferring Resistance to Multiple Drugs, Including Tigecycline, in *Klebsiella*  
426 *pneumoniae*. **mBio**, v.11, p.e02930-19, 2020.
- 427 15. NI, R. et al. The role of RND-type efux pumps in multidrug-resistant mutants of  
428 *Klebsiella pneumoniae*. **Nature**, v. 10, p.10876, 2020.
- 429 16. CLSI, Clinical and Laboratory Standards Institute, M100, 30th ed., January, 2020.
- 430 17. BrCAST, Brazilian Committee on Antimicrobial Susceptibility Testing, March, 2020.
- 431 18. BrCAST, Brazilian Committee on Antimicrobial Susceptibility Testing, May, 2021.

- 432 19. NOGUEIRA et al. Molecular insights of  $\beta$ -lactams resistance in *Klebsiella pneumoniae*  
433 isolates with focus on multidrug resistance and virulence from colonization samples. **medRxiv**,  
434 2023.
- 435 20. URZEDO, JE. et al. High mortality by nosocomial infections caused by carbapenem-  
436 resistant *P. aeruginosa* in a referral hospital in Brazil: facing the perfect storm. **J Med**  
437 **Microbiol.** v.69, n.12, p.1388-1397, 2020.
- 438 21. AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA (ANVISA). REDE  
439 NACIONAL DE MONITORAMENTO DA RESISTÊNCIA MICROBIANA EM SERVIÇOS  
440 DE SAÚDE Boletim Segurança do Paciente e Qualidade em Serviços de Saúde nº 28 -  
441 Avaliação Nacional dos indicadores de IRAS e RM, Brasília: ANVISA, 2021.
- 442 22. SADER HS, et al. Antimicrobial susceptibility of Gram-negative bacteria from  
443 intensive care unit and non-intensive care unit patients from United States hospitals (2018-  
444 2020). **Diagn Microbiol Infect Dis.** v.102, n. 1, p.115557, 2022.
- 445 23. DUNPHY LJ et al. Multidimensional Clinical Surveillance of *Pseudomonas aeruginosa*  
446 Reveals Complex Relationships between Isolate Source, Morphology, and Antimicrobial  
447 Resistance. **mSphere.** v. 6, n. 4, p. e0039321, 2021.
- 448 24. NUNES, L.H.D.S. et al., *Pseudomonas aeruginosa* in tracheal aspirate: Colonization,  
449 infection, and recurrence. **Clin Respir J.** v.17, n.5, p.439-446, 2023.
- 450 25. BABICH, T. et al., Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single  
451 Definitive Therapy for *Pseudomonas aeruginosa* Bloodstream Infection: A Multisite  
452 Retrospective Study. **Clin Infect Dis.**, v.70, n.11, p.2270-2280, 2020.
- 453 26. FREIFELD, A.G. et al. Clinical practice guideline for the use of antimicrobial agents in  
454 neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.  
455 **Clin Infect Dis**, v.52, p.e56–e93, 2011.
- 456 27. SANTOS IC, Epidemiology and antibiotic resistance trends in clinical isolates of  
457 *Pseudomonas aeruginosa* from Rio de Janeiro - Brazil: Importance of mutational mechanisms  
458 over the years (1995-2015). **Infect Genet Evol.** v. 73, p. 411-415, 2019.
- 459 28. HAIDAR, G. et al. Ceftolozanetazobactam for the treatment of multidrug-resistant  
460 *Pseudomonas aeruginosa* infections: clinical effectiveness and evolution of resistance. **Clin**  
461 **Infect Dis.** v. 65, p. 110–120, 2017.
- 462 29. MUNITA, JM. Et al. Multicenter evaluation of ceftolozane/tazobactam for serious  
463 infections caused by carbapenem-resistant *Pseudomonas aeruginosa*. **Clin Infect Dis.** v. 65, p.  
464 158–161, 2017.
- 465 30. DRAWZ, SM.; PAPP-WALLACE, KM.; BONOMO, RA. New  $\beta$ -lactamase inhibitors:  
466 a therapeutic renaissance in an MDR world. **Antimicrob Agents Chemother.** v. 58, p.1835–  
467 1846, 2014.

- 468 31. LÓPEZ-CALLEJA, AI. et al., Antimicrobial activity of ceftolozane-tazobactam against  
469 multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* clinical isolates  
470 from a Spanish hospital. **Rev Esp Quimioter.** v.32, n.1, p.68-72, 2019.
- 471 32. KARLOWSKY, JA. et al. In vitro activity of ceftazidime-avibactam against  
472 Enterobacterales and *Pseudomonas aeruginosa* isolates collected in Latin America as part of the  
473 ATLAS global surveillance program, 2017-2019. **Braz J Infect Dis.** v.25, n.6, p.101647, 2021.
- 474 33. HU, Y. et al. Prevalence, Risk Factors, and Molecular Epidemiology of Intestinal  
475 Carbapenem-Resistant *Pseudomonas aeruginosa*. **Microbiol Spectr.** v.9, n.3, p.e0134421,  
476 2021.
- 477 34. REYES, J. et al., Antibacterial Resistance Leadership Group and Multi-Drug Resistant  
478 Organism Network Investigators. Global epidemiology and clinical outcomes of carbapenem-  
479 resistant *Pseudomonas aeruginosa* and associated carbapenemases (POP): a prospective cohort  
480 study. **Lancet Microbe.** v.4, n.3, p.e159-e170, 2023.
- 481 35. CASTANHEIRA, M.; SIMNER, P.; BRADFORD, P. Extended-spectrum b-lactamases:  
482 an update on their characteristics, epidemiology and detection. **JAC Antimicrob Resist**, v. 16,  
483 n. 3, p.1-21, 2021.
- 484 36. EVANS, BA.; AMYES, SG. OXA  $\beta$ -lactamases. **Clin Microbiol Rev.** v.27, n.2, p.241-  
485 63, 2014.
- 486 37. KAITANY, KC. et al. Structures of the class D carbapenemases OXA-23 and OXA-146:  
487 mechanistic basis of activity against carbapenems, extended-spectrum cephalosporins and  
488 aztreonam. **Antimicrob. Agents Chemother.** v.57, p.4848–4855, 2013.
- 489 38. LYON, J.A. Imipenem/cilastatin: the first carbapenem antibiotic. **Drug Intell. Clin.**  
490 **Pharm.** v. 19, p.895– 899, 1985.
- 491 39. DIAS, V.C. et al. Epidemiological characteristics and antimicrobial susceptibility  
492 among carbapenem-resistant non-fermenting bacteria in Brazil. **J Infect Dev Ctries.** v.10, n.6,  
493 p.544-53, 2016.
- 494 40. LIU, LL. et al. Dissemination of blaOXA-23 in *Acinetobacter* spp. in China: main roles  
495 of conjugative plasmid pAZJ221 and transposon Tn2009. **Antimicrob Agents Chemother.** v.  
496 59, n.4, p.1998-2005, 2015.
- 497 41. ZONG, G. et al. The carbapenem resistance gene bla<sub>OXA-23</sub> is disseminated by a  
498 conjugative plasmid containing the novel transposon Tn6681 in *Acinetobacter johnsonii* M19.  
499 **Antimicrob Resist Infect Control.** v. 9, n.1, p.182, 2020.
- 500 42. HAN, L et al. blaOXA-23-like and blaTEM rather than blaOXA-51-like contributed to a  
501 high level of carbapenem resistance in *Acinetobacter baumannii* strains from a teaching hospital  
502 in Xi'an, China. **Medicine (Baltimore)**,v. 96, n. 48, p.e8965, 2017.
- 503 43. ROUHI, S.; RAMAZANZADEH, R. Prevalence of bla<sub>Oxacillinase-23</sub> and bla<sub>Oxacillinase-24/40</sub>-  
504 type Carbapenemases in *Pseudomonas aeruginosa* Species Isolated From Patients With

505 Nosocomial and Non-nosocomial Infections in the West of Iran. **Iran J Pathol.** v. 13, n. 3,  
506 p.348-356, 2018.


507 44. LEE, YT. et al. First identification of bla<sub>OXA-51</sub>-like in non-baumannii *Acinetobacter*  
508 spp. **J Chemother.** v.21, n.5, p.514-20, 2009.

509 45. NITZ, F. et al. Molecular Detection of Drug-Resistance Genes of bla<sub>OXA-23</sub>-bla<sub>OXA-51</sub> and  
510 *mcr-1* in Clinical Isolates of *Pseudomonas aeruginosa*. **Microorganisms.** v. 9, n.4, p. 786,  
511 2021.


512 46. LORUSSO, AB. et al. Role of Efflux Pumps on Antimicrobial Resistance in  
513 *Pseudomonas aeruginosa*. **Int J Mol Sci.** v.23, n.24, p.15779, 2022.

514 47. OLIVEIRA, W.K. et al. Resistome Analysis of Bloodstream Infection Bacterial  
515 Genomes Reveals a Specific Set of Proteins Involved in Antibiotic Resistance and Drug Efflux.  
516 **NAR Genom. Bioinforma.** v.2, p. lqaa055, 2020.

**(B)**




**(A)**




(A)

Genes encoding extended-spectrum  $\beta$ -lactamases  
Ambler Class A



**(B)**

**Genes encoding carbapenemases  
Ambler classes A and B**



**(C)**

**Genes encoding Ambler group D  
carbapenemases**

